Exelixis
EXEL
#1694
Rank
โ‚ฌ10.25 B
Marketcap
38,10ย โ‚ฌ
Share price
-0.02%
Change (1 day)
11.91%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): 2,09ย โ‚ฌ

According to Exelixis's latest financial reports the company's current EPS (TTM) is 2,04ย โ‚ฌ. In 2023 the company made an earnings per share (EPS) of 0,56ย โ‚ฌ an increase over its 2022 EPS that were of 0,49ย โ‚ฌ.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)2,09ย โ‚ฌ
20230,56ย โ‚ฌ14.61%
20220,49ย โ‚ฌ-22.97%
20210,64ย โ‚ฌ100%
20200,32ย โ‚ฌ-65.09%
20190,91ย โ‚ฌ-53.91%
20181,98ย โ‚ฌ333.96%
20170,46ย โ‚ฌ-260.61%
2016-0,28ย โ‚ฌ-58.75%
2015-0,69ย โ‚ฌ-42.45%
2014-1,19ย โ‚ฌ5.3%
2013-1,13ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
3,09ย โ‚ฌ 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
3,18ย โ‚ฌ 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
6,52ย โ‚ฌ 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2,55ย โ‚ฌ 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
11,19ย โ‚ฌ 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
8,97ย โ‚ฌ 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
1,48ย โ‚ฌ-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-3,15ย โ‚ฌ-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-0,72ย โ‚ฌ-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA